# Malta Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Malta HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Malta (MLT) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $364.9M - Products: 29 - Buyer markets: 29 - Average CAGR: +12.0% - Global sector size: $585.9B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $313.2B | $350.5M | $117.2B | +29.7% | 23 | +0.2% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $30.3B | $61.7K | $21.2B | -1.9% | 12 | +0.0% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $56.8B | $366.1K | $20.8B | -5.8% | 8 | +0.0% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $419.3K | $15.4B | +10.6% | 2 | +0.3% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $11.4B | $15.5K | $14.8B | +20.2% | 2 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $23.0B | $4.4M | $13.9B | +28.9% | 7 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $684.6K | $11.7B | +43.5% | 2 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $14.3B | $1.4M | $9.5B | +7.7% | 4 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $94.6K | $8.0B | +5.3% | 4 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $9.3B | $450.2 | $7.4B | +6.0% | 3 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $17.0B | $26.5K | $7.3B | +3.0% | 4 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.5B | $1.1K | $7.1B | +16.3% | 2 | +0.0% | | HS 300220 - Vaccines: for human medicine | $6.4B | $186.0K | $5.0B | -14.9% | 3 | +0.0% | | HS 330300 - Perfumes and toilet waters | $8.5B | $1.8M | $5.0B | +1.4% | 3 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $137.6 | $4.9B | -38.0% | 1 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $682.0 | $4.8B | -8.0% | 1 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $7.5B | $72.0K | $3.5B | +161.2% | 1 | +0.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.6B | $154.4K | $3.4B | -25.3% | 2 | +0.0% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $17.9K | $3.3B | -3.2% | 2 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $240.3K | $2.9B | +21.5% | 2 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $20.7K | $2.2B | -5.9% | 2 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $192.1 | $2.1B | -14.6% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.9M | $2.0B | +56.8% | 1 | +0.1% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $8.6 | $1.4B | -18.4% | 1 | +0.0% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $138.0K | $1.2B | +48.3% | 1 | +0.5% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $18.2 | $1.1B | -39.0% | 1 | +0.0% | | HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $573.5 | $1.1B | -18.3% | 1 | +0.0% | | HS 293410 - Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure | $890.3M | $38.9K | $1.1B | +4.0% | 1 | +0.0% | | HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $2.4M | $986.8M | +23.3% | 1 | +0.3% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $55.5B calculated opportunity across 12 products. - Germany (DEU): $42.2B calculated opportunity across 15 products. - Switzerland, Liechtenstein (CHE): $33.3B calculated opportunity across 3 products. - Italy (ITA): $23.8B calculated opportunity across 4 products. - Netherlands (NLD): $21.7B calculated opportunity across 7 products. - Slovenia (SVN): $21.3B calculated opportunity across 3 products. - China (CHN): $14.8B calculated opportunity across 5 products. - United Kingdom (GBR): $12.2B calculated opportunity across 6 products. - Spain (ESP): $10.4B calculated opportunity across 5 products. - France (FRA): $8.9B calculated opportunity across 5 products. - Belgium (BEL): $8.1B calculated opportunity across 2 products. - Canada (CAN): $7.2B calculated opportunity across 4 products. ## Growth stars - HS 300212: +161.2% average CAGR, $3.5B calculated opportunity. - HS 300420: +56.8% average CAGR, $2.0B calculated opportunity. - HS 293339: +48.3% average CAGR, $1.2B calculated opportunity. - HS 293359: +43.5% average CAGR, $11.7B calculated opportunity. - HS 300490: +29.7% average CAGR, $117.2B calculated opportunity. - HS 300439: +28.9% average CAGR, $13.9B calculated opportunity. - HS 294190: +23.3% average CAGR, $986.8M calculated opportunity. - HS 293590: +21.5% average CAGR, $2.9B calculated opportunity. - HS 293719: +20.2% average CAGR, $14.8B calculated opportunity. - HS 330210: +16.3% average CAGR, $7.1B calculated opportunity. ## Diversification opportunities - HS 300490: 23 buyer markets, $117.2B calculated opportunity. - HS 382499: 12 buyer markets, $21.2B calculated opportunity. - HS 300215: 8 buyer markets, $20.8B calculated opportunity. - HS 300439: 7 buyer markets, $13.9B calculated opportunity. - HS 293499: 4 buyer markets, $9.5B calculated opportunity. - HS 330499: 4 buyer markets, $8.0B calculated opportunity. - HS 382200: 4 buyer markets, $7.3B calculated opportunity. - HS 382600: 3 buyer markets, $7.4B calculated opportunity. - HS 300220: 3 buyer markets, $5.0B calculated opportunity. - HS 330300: 3 buyer markets, $5.0B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.